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A b s t r a c t
Introduction: The oxidative stress contributes to all three phases of carci-
nogenesis and represents a  concomitant condition in renal cell carcinoma 
(RCC). RCC is the most common type of neoplasm of the kidney, and despite 
numerous studies the set of predictive and prognostic markers of survival 
are still unknown. The aim of our study was to examine the relation between 
antioxidant (AO) status and overall survival (OS) in RCC patients. 
Material and methods: Our study included 95 patients with RCC, who 
underwent radical nephrectomy. We analysed the prognostic role of anti-
oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, 
glutathione S-transferase, glutathione reductase, glutathione, and malondi-
aldehyde) and other clinicopathological factors (size, grade, stage, and his-
tological subtype) on the OS of RCC patients.
Results: The 5-year OS was 54.6%. The survival analysis related to AO pa-
rameters showed no significant difference in survival of RCC patients. The 
concentration of malondialdehyde, an indicator of lipid peroxidation, also 
had no significant effect on the survival rate of RCC patients. Univariate 
and multivariate analysis confirmed the significance of clinicopathological 
parameters (size, p < 0.001; Fuhrman grade, p = 0.001, and stage, p < 0.001) 
for patients’ survival.
Conclusions: In our cohort of patients, different antioxidant parameters 
were not found to be predictors for OS of patients with RCC, who underwent 
radical nephrectomy.  
Key words: renal cell carcinoma, oxidative stress, overall survival, 
prospective study.
Introduction
Renal cell carcinoma (RCC) is a heterogeneous disease that includes 
histological entities characterised by different aetiology, morphology, 
and outcome. Three histological subtypes: clear cell (ccRCC), papillary 
(pRCC), and chromophobe (chRCC) account for 85–90% of all RCC cas-
es  [1]. The incidence of RCC is constantly increasing in North Ameri-
ca and Europe  [2] with the exception of Finland and Estonia where it 
has been stable [3]. The majority of cases (80%) occur after the age of 
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40 years, and the incidence rate is higher among 
men compared with women (3 : 2) [4]. A reliable 
causative agent of RCC is still unknown, but ex-
isting evidence points to chromosomal defects 
contributing to its development [5]. Objective di-
agnostic biomarkers and effective targeted thera-
peutics are also lacking [6].
The intensive metabolic activity of tubular epi-
thelial cells, glomerular cells, and activated mac-
rophages make them the main generators of re-
active oxygen species (ROS) in human kidneys [7]. 
At the subcellular level, ROS are produced in the 
process of oxidative phosphorylation in mito-
chondria and as a  product of membrane-bound 
protein NADPH oxidases (NOX family) [8]. Under 
physiological conditions, ROS have a role as sig-
nalling molecules, and their physiological level 
is maintained by an antioxidant (AO) system. 
The AO system of the kidneys is based on small 
scavenging molecules like glutathione (GSH) and 
enzymes, which catalytically modify ROS into 
less harmful forms. Superoxide dismutase (SOD), 
catalase (CAT), and the glutathione peroxidase 
family (GPxs) are the main enzymes involved 
in AO defence. Glutathione reductase (GR) and 
glutathione S-transferase (GST) are glutathione-
dependent enzymes, which additionally contrib-
ute to the AO ability of the kidneys [9]. Oxidative 
stress is a condition related to kidney cancer [10] 
and is mediated through a  reduction in cellular 
antioxidant pool [11].
Efforts are still ongoing to find the set of pre-
dictive and prognostic markers of survival in pa-
tients with RCC [12]. Taking into account the sig-
nificance of oxidative stress for all three phases of 
cancer development and the role of the AO system 
in preventing its process [13], we examined the re-
lation between AO status and overall survival (OS) 
among RCC patients who underwent radical ne-
phrectomy. 
Material and methods
Subjects 
We analysed 95 patients with RCC, who un-
derwent radical nephrectomy in several Urology 
Clinics in Belgrade, Serbia, between 2009 and 
2013. The study was performed in compliance 
with the ethical principles of the Declaration of 
Helsinki and all applicable national laws and 
regulations. The clinicopathological features of 
patients included age, gender, size, grade, stage, 
and histological classification. For tumour histol-
ogy, the 2004 WHO classification [1] was used and 
tumours were graded according to the Fuhrman 
grading system [14]. OS time was determined from 
the surgery date until death or the last follow-up 
appointment. The follow-up period was 5  years 
(median: 38 months, IQR  =  31–42 months). The 
median age of patients at diagnosis was 62 years 
(IQR = 58–66.2 years).
Specimens
For the enzyme activity measurement, the tis-
sue was washed in a saline solution (PBS) at pH 
7.4 in order to remove blood cells. All samples were 
homogenised on ice in eight volumes of cold potas-
sium phosphate buffer (0.05 M KH
2
PO
4
, 0.0001 M 
EDTA, pH 7.4) by using Ultra-Turrax Homogeniser 
(IKA® T10 basic ULTRA-TURRAX®, IKA Werke GmbH 
& Co.KG, Staufen, Germany) at 25,000 rpm for 15 s 
in four cycles. Homogenates were left overnight 
at –70°C to disrupt cell membranes. The thawed 
homogenates were vortexed for 1 min and then 
centrifuged (10000 × g, 15 min, 4°C) and the up-
per layer was collected and kept at –70°C till the 
assay.
For GSH and total malondialdehyde (MDA) con-
centration measurement, the tissue was prepared 
as recommended by the kit producer (BIOXYTECH® 
GSH-420TM and BIOXYTECH® MDA-586TM respec-
tively, OXIS International Inc., Foster City, CA, USA). 
Assays
The protein concentration was measured with 
PierceTM BCA Protein Assay Kit (Thermo Fisher Sci-
entific, Rockford, IL, USA). The method is based 
on a combination of the biuret reaction and colo-
rimetric detection of cuprous cation (Cu+1) with 
bicinchoninic acid (BCA). The cupric cation (Cu+2) 
is reduced by the sample proteins in an alkaline 
medium to Cu+1. Two molecules of BCA react with 
one Cu+1 making a  purple-coloured product that 
absorbs at 562 nm. The protein concentration was 
expressed as mg/ml of the sample.
Total SOD activity was measured using Su-
peroxide Dismutase Assay Kit (Cayman Chemical 
Company, Ann Arbor, MI, USA). The assay is based 
on the reaction between tetrazolium salt and su-
peroxide radicals (O
2
.-), which results in forma-
zan dye development. SOD inhibits this reaction 
by dismutation of O
2
.-, generated by xanthine 
oxidase. The intensity of formazan dye was mea-
sured at 450 nm using a microplate reader (Wal-
lac1420 Victor2, PerkinElmer Inc., Waltham, MA, 
USA). One unit of SOD is defined as the amount 
of enzyme needed to exhibit 50% dismutation of 
superoxide radical.
Catalase activity measurement was performed 
by the method of Beutler (1984) [15]. The method 
is based on the ability of CAT to decompose hy-
drogen peroxide in an incubation mixture to wa-
ter and oxygen. The incubation mixture contains 
50 µl of a Tris-HCl buffer (1 M Tris-HCl, 5 mM EDTA, 
pH 8.0), 900 µl of a substrate (10 mM H
2
O
2
) and 
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30 µl of distilled water. The reaction starts after 
adding 20 µl of the sample. Decomposition of H
2
O
2 
was monitored for 3 min at 230 nm and 37°C us-
ing a  spectrophotometer (UV Line 9400, SI Ana-
lytics GmbH, Mainz, Germany). One unit of CAT 
activity is defined as the amount of enzyme that 
degrades 1 µmol of H
2
O
2
 per minute under assay 
conditions. The extinction coefficient for H
2
O
2 
at 
230 nm is 0.071 mM–1cm–1. 
Glutathione peroxidase activity was assessed 
by the BIOXYTECH® GPx-340TM Assay (Oxis Inter-
national, Inc., Foster City, CA, USA). The assay is 
based on reduction of organic peroxide, which 
produces oxidised glutathione (GSSG) immediate-
ly reduced to GSH by GR with concomitant oxida-
tion of NADPH to NADP+ and a decrease in absor-
bance at 340 nm. The absorbance decrease was 
measured spectrophotometrically, and it is direct-
ly proportional to the GPx activity in the sample. 
The extinction coefficient for NADPH at 340 nm is 
6220 M–1cm–1. One unit of GPx activity causes the 
oxidation of 1 µmol of NADPH per minute under 
the assay conditions.
Glutathione S-transferase activity was mea-
sured using Glutathione S-Transferase Assay 
Kit (Cayman Chemical Company, Ann Arbor, MI, 
USA). The assay utilises the conjugation of CDNB 
(1-chloro-2,1-dinitrobenzene) and GSH accom-
panied by an increase in absorbance at 340 nm. 
The extinction coefficient for CDNB at 340 nm is 
0.0096 µM–1cm–1. One unit of GST will conjugate 
1 nmol of CDNB with GSH per minute at 25°C. 
Glutathione reductase activity was determined 
using the BIOXYTECH® GR-340TM Assay (OXIS In-
ternational, Inc., Foster City, CA, USA). The assay 
is based on catalysed reduction of GSSG to GSH 
and oxidation of NADPH to NADP+. The oxidation 
of NADPH results in a decrease of absorbance at 
340 nm as a function of time. The molar extinction 
coefficient for NADPH at 340 nm is 6220 M–1cm–1. 
One unit of GR activity is defined as the amount 
of enzyme catalysing the reduction of 1 µmol of 
GSSG per minute under assay conditions. 
Total GSH concentration was determined by 
the BIOXYTECH® GSH-420TM Assay (OXIS Interna-
tional, Inc., Foster City, CA, USA). The measurement 
is based on a  three-step colourimetric reaction. 
The reducing agent, TCEP (Tris[2-carboxyethyl] 
phosphine), reduces all oxidised glutathione pres-
ent in the sample. In the next step chromogen 
(4-chloro-1-methyl-7-trifluoromethylquinolinium 
methylsulfate) is added, reacting with all thiols in 
the sample and forming thioethers. NaOH raises 
the pH of the reaction mixture to over 13 and leads 
to chromophoric thione development as a result of 
β-elimination specific to the GSH-thioether. The 
absorbance measured at 420 nm is directly pro-
portional to the GSH concentration. 
Total MDA concentration was determined us-
ing BIOXYTECH® MDA-586TM Assay (OXIS Interna-
tional, Inc., Foster City, CA, USA). The protocol is 
based on hydrolysis of the sample in the presence 
of butylated hydroxytoluene (BHT) at low pH (1-2) 
at 60°C for 80 min. After hydrolysis, free MDA 
reacts with the chromogenic reagent (N-methyl-
2-phenylindole, NMPI) for 60 min at 45°C. The 
reaction yields a carbocyanine dye that can be de-
tected at 586 nm. 
The enzyme activities were expressed as units 
(U) or mU per milligram of proteins (U/mg or 
mU/mg). Concentration of GSH and MDA were 
expressed as nmol/mg of proteins.
Statistical analysis
Statistical analysis was performed with SPSS 
23.0 for Windows (SPSS Inc., Chicago, IL, USA). The 
OS rate was calculated by Kaplan-Meier method, 
and groups were compared using Log-rank statis-
tics. The compared groups of AO parameters were 
made by cut-off points based on median value of 
enzyme activity or MDA and GSH concentration, 
as previously reported [16]. Univariate and multi-
variate Cox proportional hazards regression model 
were used to analyse the independent factors re-
lated to 5-year OS. P-values < 0.05 were consid-
ered significant.
Results
Clinical findings
Clinicopathological characteristics of patients 
are given in Table I. The majority of patients were 
between ages 61 and 70 years, and both genders 
were almost equally represented. The median tu-
mour size was 7 cm (IQR = 5–8.2 cm). The majority 
of tumours were up to 7 cm in diameter (63.1%). 
Low-grade (I–II) RCC was diagnosed in the majori-
ty of patients. Stages 1 and 3 were most frequently 
recorded, and ccRCC was the most common histo-
logical subtype at the time of diagnosis.
Survival analysis
The OS for all patients was 96.8%, 73.7%, and 
54.6% after 1, 3, and 5 years, respectively (Fig-
ure  1  A). Statistically significant correlations ex-
isted between survival and age (log-rank 13.999, 
p = 0.003), tumour size (log-rank, 22.540, p < 0.001), 
grade (log-rank 12.080, p = 0.001), and stage (log-
rank 26.217, p < 0.001) (Figures 1 B–E).
In each age group the 5-year OS rate was as 
follows: 84.6% among patients younger than 
50 years, 70% among patients aged 51–60 years, 
33.9% among patients aged between 61–70 years, 
and 61.8% among those older than 70 years (Fig-
ure 1 B). The rates of OS after 1, 3, and 5 years for 
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patients with RCC size ≤ 4 cm were 100%, 77.8%, 
and 70.7%, respectively; patients with tumour 
size 4.1–7 cm had survival rates of 97.6%, 87.7%, 
and 70.4% after 1, 3, and 5 years. After 5 years 
of follow-up, 60.2% of patients with RCC size 
7.1–10 cm were still alive. None of the patients 
with tumour size > 10 cm were alive after 5 years 
(Figure 1 C).
After 5 years, survival among subjects with 
low-grade tumours was 64.3%. In the high-grade 
tumour group, the survival rate was 96.6, 55.2, 
and 34.5% after 1, 3, and 5 years, respectively (Fig-
ure 1 D). Patients with low-stage tumours (stage 
1 and 2) had survival rates of 77.2% and 77.9%, 
respectively, while 34% of patients with stage 3 
were alive after a  5-year follow-up period. None 
of the patients with stage 4 RCC were alive after 
5 years (Figure 1 E). As regards histological sub-
types, after 5 years the better survival rate (61.4%) 
was observed in patients with ccRCC compared 
to those with the pRCC (36.9%), while chRCC 
patients showed survival rates of 100%, 64.3%, 
and 0% after 1, 3, and 5 years, respectively (Fig-
ure 1 F). There was no significant association be-
tween gender, histological subtype, and survival 
rate (log-rank 0.002; p  =  0.962, log-rank 2.424, 
p = 0.298, respectively). 
The OS analysis based on the AO enzymes 
(Table II) revealed no statistically significant differ-
ence between the median values in survival rates. 
Also, Kaplan-Meier test showed no significant in-
fluence of lipid peroxidation parameter (MDA) and 
GSH concentration on survival of RCC patients.
Univariate analysis (Table III) showed that size, 
Fuhrman grade, and stage were significant prog-
nostic factors for OS. The size (> 10 cm) and high 
Fuhrman grade (III–IV) remained independent 
predictors of survival in multivariate analysis. Age, 
as a confounding variable, was excluded from the 
analysis. 
Discussion
Oxidative stress plays a  crucial role in the 
pathogenesis of various malignancies, including 
RCC. ROS can induce the carcinogenesis process 
and sustain tumour progression by damaging 
DNA and can directly activate cellular pathways 
of signal transduction, which are associated 
with malignant transformation. It was previ-
ously dem onstrated that changes occurred in 
the oxidative stress/antioxidant status bal ance 
at the cellular level during the tumour growth 
process [17, 18]. Previous studies have shown 
significantly reduced expression and activity of 
AO enzymes in cancerous tissue of the kidneys 
[19, 20]. Moreover, the enzymatic source of ROS is 
overactive [21] resulting in increased level of oxi-
dative stress in patients with RCC [22–25]. Based 
on these findings, permanent oxidative stress is 
a feature of RCC. 
Prognostic significance of AO enzyme activi-
ties, MDA, and GSH levels in patients with RCC 
was not confirmed in this study. However, we 
observed a  prospective influence of GPx, GR, 
and GSH on survival. Studies indicate the im-
portance of GSH and its metabolising enzyme, 
g-glutamyl transferase (GGT), which were found 
to be elevated in pathological states of oxidative 
stress and linked to tumour growth and survival. 
Glutathione is a  major cell provider of cysteine, 
which is especially critical for protein synthesis in 
rapidly dividing neoplastic cells [26]. The study of 
Hofbauer et al. [27] showed that pretherapeutic 
Table I. Clinicopathological characteristics of pa-
tients with renal cell carcinoma (N = 95)
Characteristic Occurrence
N (%)
Age:
≤ 50 17 (17.9)
51–60 18 (18.9)
61–70 43 (45.3)
> 70 17 (17.9)
Gender:
Male 51 (53.7)
Female 44 (46.3)
Size of tumour [cm]:
≤ 4 18 (18.9)
4.1–7 42 (44.2)
7.1–10 18 (18.9)
> 10 17 (17.9)
Grade:
Low 66 (69.5)
High 29 (30.5)
Stage:
1 37 (38.9)
2 14 (14.7)
3 40 (42.1)
4 4 (4.2)
Histology:
Clear cell 74 (77.9)
Papillary 13 (13.7)
Chromophobe 8 (8.4)
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serum GGT was an independent prognostic fac-
tor for patients with RCC, with higher levels being 
associated with worse outcomes. It was shown 
that contrary to enzyme expression on the lumi-
nal surface of secretory and absorptive cells in 
normal kidney tissue, GGT is expressed over the 
entire cell surface in RCC. This may subsequently 
lead to elevated levels of GGT and higher intra-
cellular levels of GSH, which correlate with the 
tumour burden [27]. However, Ganesamoni et al. 
[22] observed a  lower glutathione concentration 
in association with higher grade RCC and meta-
static disease.
Earlier studies also show different results re-
garding other AO parameters in RCC. Glutathione 
peroxidase activity in RCC tissue was reported 
to be significantly decreased in one study [20] 
whereas it was unchanged in another [25].
Figure 1. Survival in 95 patients with renal cell carcinoma. A – overall survival; survival according to: age (B), tumour 
size (C), Fuhrman grade (D), stage (E), histological subtype (F)
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The lipid peroxidation level was found to be 
higher in RCC than in normal renal tissue, and 
higher tumour grade was associated with in-
creased lipid peroxidation in tumour tissue [22]. 
Vieira de Ribeiro et al. [28] found overexpression 
of SOD-1 in ccRCC extracts, which was explained 
by the fact that the production of ROS is general-
ly more active in malignant cells. Although higher 
SOD level and lower CAT in tumour tissue were 
reported [22], no association of SOD level, histo-
pathological findings, tumour grade, and stage 
was observed. Some recent findings suggest no 
correlation between tumour staging and serum 
levels of SOD, GPx, GST, MDA, and GSH levels [29]. 
In our study, we did not observe an association 
between GST level and OS; however, other inves-
tigators considered GST to be a  highly specific 
diagnostic marker for primary conventional RCC, 
in which it is a prognostic marker if the grade is 
omitted from the multivariate analysis [30].
The findings of this study indicate that the 
5-year OS was ~55%, and it was within the range 
of contemporary data [3]. In univariate analysis, 
tumour size, pathological stage, and Fuhrman 
grade were independent predictors of OS. The size 
and grade remained significantly associated with 
OS after multivariate analysis. The Kaplan-Meier 
analysis indicated a  possible role of the antioxi-
dant GPx/GR activity and the GSH content for OS 
in these patients because the obtained signifi-
cance values were near borderline. 
Tumour size is considered as an important de-
terminant of the UICC/AJCC (International Union 
Against Cancer/American Joint Commission on 
Cancer) TNM stage, which correlates with re-
nal sinus invasion, metastatic potential, and 
RCC prognosis [31]. In our patients, the tumours 
with worse prognosis were larger than 7 cm. 
The risk of death for patients with tumour size 
of 7.1–10 cm and > 10 cm was 1.2 and 4.1 times 
higher, respectively. Studies on large cohorts 
have shown that in patients with ccRCC, each 
1 cm increase in tumour size increased the odds 
of a high Fuhrman grade (III–IV) compared with 
a  low Fuhrman grade (I–II) tumour by 25% [32]. 
Although tumour stage was a prognostic marker 
affecting survival, it was not proven to be an in-
dependent parameter in multivariate analysis. 
The prognostic value of tumour grade observed 
in our study is in accordance with previous data. 
Most authors agree that Fuhrman grade and tu-
mour stage are the strongest independent prog-
nostic factors for RCC [33–36]. 
Some limitations of our study need to be ad-
dressed. It is likely that the relatively small num-
ber of analysed cases (95 patients) and group 
heterogeneity may have underestimated the 
prognostic effect of tumour stage, because the 
tumour stage is among the most recognised 
prognostic factors. A larger sample size would 
also provide a better evaluation of the potential 
prognostic significance of AO parameters, judg-
ing by certain borderline significances observed 
in this study.
In conclusion, in our cohort of patients, we 
identified histopathological features of tumours 
as independent prognostic factors in RCC. No cor-
relation was observed between AO status and OS. 
New studies are needed to provide better insight 
into cellular bi ology of oxidation and AO defence 
mechanisms, aiming to find prognostic biomark-
ers for patients with RCC.
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Table II. Kaplan-Meier analysis of antioxidant sta-
tus parameters in patients with renal cell carcinoma
Oxidant/AO  
parameter
(>/≤ median value)
Log-rank P-value
SOD [U/mg]:
≤ 59.38 2.373 0.123
> 59.38
CAT [U/mg]:
≤ 10.22 2.418 0.120
> 10.22
GPx [mU/mg]:
≤ 3.36 3.506 0.061
> 3.36
GST [mU/mg]:
≤ 3.33 0.907 0.341
> 3.33
GR [mU/mg]:
≤ 7.53 3.063 0.080
> 7.53
GSH [nmol/mg]:
≤ 58.26 3.488 0.062
> 58.26
MDA [nmol/mg]:
≤ 2.03 0.208 0.648
> 2.03
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Table III. Factors affecting overall survival in patients with renal cell carcinoma
Variable Univariate analysis
Coefficient β HR 95% CI P-value
Size of tumour [cm]:   < 0.001
≤ 4 1.0 –
4.1–7 –0.213 0.808 0.276–2.370 0.698
7.1–10 0.152 1.164 0.354–3.828 0.803
> 10 1.417 4.124 1.482–11.476 0.007
Grade:
Low 1.0 –
High 1.115 3.051 1.567–5.941 0.001
Stage: < 0.001
1 1.0 –
2 –0.302 0.739 0.154–3.560 0.707
3 1.280 3.596 1.535–8.424 0.003
4 2.473 11.861 3.353–41.959 < 0.001
GPx [mU/mg]:
≤ 3.36 1.0
> 3.36 0.649 1.9 0.954–3.841 0.068
GR [mU/mg]:
≤ 7.53 1.0
> 7.53 0.598 1.819 0.918–3.604 0.087
GSH [nmol/mg]:
≤ 58.26 1.0
> 58.26 0.650 1.916 0.952–3.854 0.068
Variable Multivariate analysis
Coefficient β HR 95% CI P-value
Size of tumour [cm]: 0.023
≤ 4 1.0
4.1–7 –1.027 0.358 0.109–1.172 0.090
7.1–10 –1.030 0.357 0.087–1.468 0.153
> 10 0.341 1.406 0.4–5.2 0.611
Grade:
Low 1.0 –
High 1.469 4.345 1.915–9.862 < 0.001
Stage: 0.101
1 1.0 –
2 –0.080 0.923 0.174–4.900 0.925
3 1.197 3.309 1.123–9.750 0.030
4 0.829 2.290 0.424–12.368 0.335
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